MedTrace Logo

SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries

NCT00114972 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1800

Last updated 2010-06-23

Study results available
· View outcomes & findings →

Summary

The SYNTAX trial is designed to determine the best treatment for patients with complex coronary disease (blocked or narrowed arteries in both the right and left sides of the heart) by randomizing patients to receive either percutaneous coronary intervention (PCI) with polymer-based paclitaxel-eluting TAXUS stents or to coronary artery bypass surgery (CABG).

Conditions

Interventions

DEVICE

Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent

Drug Eluting Stent

PROCEDURE

Coronary Artery Bypass Surgery

Coronary Artery Bypass Surgery

Sponsors & Collaborators

  • Cardialysis BV

    collaborator INDUSTRY

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Patrick W. Serruys, MD, PhD · Erasmus Medical Center

  • Friedrich W Mohr, MD · Heart Center Leipzig - University Hospital

  • Monika Hanisch, PhD · Boston Scientific Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2008-04-30
Completion
2012-05-31

Countries

  • United States
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Hungary
  • Italy
  • Latvia
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00114972 on ClinicalTrials.gov